Inotiv, Inc. (NOTV)
AI stock analysis · as of Jun 8, 2026
Loading microstructure…
Inotiv (NOTV) is a contract research organization providing nonclinical drug discovery and safety assessment services (DSA) alongside research models (RMS). The company filed Chapter 11 bankruptcy in June 2026 to restructure $326M of debt with $65M DIP financing. The core investment question is moot in the traditional sense: this is a distressed equity stub trading at $0.17 with a $5.9M market cap, where equity holders in Chapter 11 historically face near-total wipeout. Any 'investment' here is a binary speculation on residual recovery, not a fundamentals-based thesis.
valuationDistressed/optionality pricing — P/S 0.011x and P/B 0.075x are not 'cheap multiples' but rather the market pricing in a high probability of equity wipeout in Chapter 11; EV/EBITDA of ~56x reflects debt dominating enterprise value with minimal EBITDA support.
This analysis is from Jun 8, 2026. Want the latest on NOTV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · DSA segment is still growing and profitable: service revenue +3.4% YoY in Q2 FY2026 and segment operating income improved to $6.1M from $5.0M — a viable business exists post-restructuring
- · Price-to-sales of 0.011x and price-to-book of 0.075x reflect an extreme distressed discount; any non-zero equity recovery from the plan implies large percentage upside from $0.17
- · Short interest at 9.47% of float with 2.53 days to cover creates squeeze potential on any positive restructuring headline or speculative retail flow (the news already cited a 34% April spike)
- · $65M DIP financing was secured, indicating lenders see going-concern value worth preserving, which improves odds of an orderly reorganization vs. liquidation
- · Strategic value of the underlying CRO platform (1,945 employees, $513M revenue base, international footprint) gives reorganized entity a credible path to emerge
Bear case
- · Chapter 11 was filed in June 2026 — equity holders are last in line behind $416M of debt, and with equity already eroded to $77M (from $136M six months prior), residual value to common is likely zero
- · Debt-to-equity of 632x and total debt of $459M against only $21.7M cash makes any pre-petition equity recovery mathematically improbable
- · RMS segment is in sharp decline: -10.7% revenue and operating income collapsed from $15.6M to $9.1M — the 'good' half of the business is shrinking
- · FY2026 H1 net loss widened to $60.8M from $42.5M; operating loss nearly doubled to $35.6M, showing the operational situation worsened into the filing
- · CEO insider share sale ahead of the bankruptcy filing, missed April 2026 interest payment, and DOJ fines plus securities class action create overhang and signal poor governance
- · Customer concentration risk (15.2% from one client) and ongoing cybersecurity remediation costs ($2.6M in H1) further pressure the reorganized business
Catalysts
- · Chapter 11 plan of reorganization filing and disclosure statement — defines whether existing equity gets any recovery, warrants, or is cancelled
- · Next earnings date August 5, 2026 — first post-petition financials will clarify DIP burn rate and operating trajectory
- · Court hearings on lender treatment, asset sales, or 363 sales of segments (DSA vs RMS could be sold separately)
- · Potential short squeeze on restructuring headlines given 9.5% short float and thin $5.9M market cap
- · Emergence from Chapter 11 with new capital structure — historically the catalyst that either confirms wipeout or, rarely, delivers stub equity recovery
Key risks
- · Equity cancellation in the plan of reorganization — the modal outcome in Chapter 11 for deeply underwater capital structures
- · Conversion to Chapter 7 liquidation if DIP milestones are missed, eliminating going-concern value
- · Further RMS revenue erosion during bankruptcy as customers shift to non-distressed CRO competitors (Charles River, Labcorp)
- · Cross-default and acceleration dynamics across Term Loan, Convertible Notes, and Second Lien PIK Notes leave no daylight for equity
- · Delisting from Nasdaq during bankruptcy proceedings, pushing the stock to OTC and reducing liquidity
What to watch
- · August 5, 2026 earnings release and any post-petition operating update
- · Filing of disclosure statement and plan of reorganization — specifically equity treatment language
- · DIP budget variance reports and any 363 asset sale announcements (DSA carve-out potential)
- · Nasdaq listing status notifications — delisting would mark a step-function down in liquidity
- · Short interest trend and any squeeze episodes given 9.5% short float on a $5.9M cap stock
- · Key price level: $0.08 52-week low as the floor; sustained breaks below increase wipeout probability pricing
Key metrics
Price target rationale
Base case $0.05 assumes the plan provides minimal token equity recovery or out-of-the-money warrants typical of Ch.11 restructurings where the business survives but equity is heavily diluted/cancelled. Bull case $0.40 reflects a low-probability scenario where a strategic buyer or favorable plan preserves some stub equity, combined with potential short-squeeze dynamics on the thin float. Bear case $0.00 reflects the modal Ch.11 outcome of full equity cancellation given $416M debt vs. eroding $77M book equity.
On Wall Street's view (disagree): The legacy 'strong_buy' recommendation appears stale (latest analyst action on file is a May 2024 downgrade from Lake Street, with no targets currently published) and predates the Chapter 11 filing. No credible sell-side framework supports buying pre-petition equity at this stage of distress.
Latest filing (10-Q)
Inotiv is a CRO in acute financial distress — $416M in debt all due within 12 months, only $15M cash, a missed bond interest payment, lender covenant waivers expiring imminently, and management openly flagging going concern doubt while racing to find a restructuring deal.
Inotiv, Inc. (NOTV) is a contract research organization (CRO) providing nonclinical drug discovery and safety assessment services to pharmaceutical and biotech companies, and selling research-quality animals, diets, and related products to biopharma, academic, and government clients. Revenue is split roughly equally between services (DSA segment) and products (RMS segment). The company operates primarily in the US and Netherlands.
What the news says · bearish
The dominant storyline for NOTV is a rapid deterioration into bankruptcy. After months of warning signs — repeated liquidity covenant waivers, a missed interest payment on its 2027 notes, a CEO share sale, and a $40M emergency bridge loan — Inotiv filed for Chapter 11 in early June 2026 to restructure $326M in debt and secure $65M in DIP financing. While there were brief intermittent rallies (a 34% spike in April and a Q2 earnings-driven bounce in May), these appear to have been speculative moves against a fundamentally distressed backdrop. The bankruptcy filing is the defining event, and equity holders in Chapter 11 proceedings typically face near-total wipeout, making the stock extremely high-risk.
This analysis is from Jun 8, 2026. Markets move. Get the current read on NOTV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.